Anti-F11 therapeutic antibody (Pre-made Abelacimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Abelacimab (previously known as MAA 868) is a fully human, factor XI monoclonal antibody, being developed by Anthos Therapeutics under the license from Novartis, for the prevention of cardiovascular disorders including stroke due to thrombosis and thromboembolism in patients with atrial fibrillation.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-002-1mg	1mg	3090
GMP-Bios-ab-002-10mg	10mg	21890
GMP-Bios-ab-002-100mg	100mg	148000
GMP-Bios-ab-002-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-F11 therapeutic antibody (Pre-made Abelacimab biosimilar,Whole mAb)
INN Name	Abelacimab
Target	F11
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Unknown
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	6r8x:CB
Year Proposed	2018
Year Recommended	2019
Companies	Novartis
Conditions Approved	na
Conditions Active	Venous Thromboembolism; Stroke;Thrombosis
Conditions Discontinued	na
Development Tech	na